Table 3.

Table showing relative agonist efficacies and potencies of the ligands for transrepression via the GR on AP-1 or NFκB cis-elements and the IL6 gene^*

	Transrepression
	COS-1				PBMC
	AP-1		NFκB		IL6
Ligand	MAX (%) ± SEM	EC50 (M) ± SEM	MAX (%) ± SEM	EC50 (M) ± SEM	MAX (%) ± SEM	EC50 (M) ± SEM
DEX	100 ± 0.0a	7.24 ± 1.57 × 10−14a	100 ± 0.0a	1.08 ± 0.38 × 10−14a	100 ± 9.16a	7.63 ± 6.31×10−9a
MPA	96.94 ± 4.60a	2.49 ± 0.64 × 10−11b	84.46 ± 4.92a	2.84 ± 1.88 × 10−14a, c	101.62 ± 11.50a	0.92 ± 1.45×10−8a
NET	33.86 ± 9.97b	3.58 ± 2.85 × 10−9 #c	32.63 ± 9.86b	8.35 ± 5.65 × 10−13# a,b,c	57.95 ± 9.55$a	4.66 ± 4.32×10−9$a
LNG	39.60 ± 4.31b	3.32 ± 2.89 x 10−10 #b,c	38.04 ± 9.70b	5.00 ± 3.00 × 10−13# a,b,c	88.53 ± 14.82a	2.95 ± 6.27×10−8a
ETG	79.60 ± 7.27a	2.90 ± 0.99 × 10−10b,c	81.65 ± 7.32a	6.04 ± 3.49 × 10−11b	77.19 ± 17.00a	2.44 ± 0.10×10−8a
NES	92.03 ± 4.39a	5.41 ± 3.06 × 10−10b,c	85.66 ± 8.58a	3.49 ± 2.05 × 10−11b,c	100.13 ± 7.92a	5.49 ± 5.82×10−9a

^*Data shown in Fig. 2C-E, were analyzed to obtain the MAX (%) ± SEM and EC₅₀ (M) ± SEM, values for each ligand for the GR.

^#The EC₅₀ values for NET and LNG should be interpreted with caution as very weak agonist activity was observed.

^$The MAX and EC₅₀ values for NET should be interpreted with caution as Prism 9 deemed this curve unstable due to variable data.

^a,b,cStatistical significance between treatment groups was determined using one-way ANOVAs with Tukey post-test.